secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001193125-21-244709
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q2 net loss $19.3M; cash $806.6M; NUV-422 trial expands
--------------------------------------------------------------------

- Net loss of $19.3M ($0.09/share) vs $8.6M loss ($0.10) in Q2 2020.
- Cash, cash equivalents and marketable securities $806.6M as of June 30.
- R&D expenses $14.0M, up from $7.3M, on higher clinical and preclinical costs.
- Phase 1/2 of NUV-422 expanded to glioblastoma, breast, and prostate cancers; Phase 1 data expected 2022.
- Appointed David C. Hanley as Chief Technical Operations Officer in June 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312521244709/0001193125-21-244709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312521244709/d212585d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-244709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer